Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
was the conserved vis viva. It was later shown that both quantities are conserved simultaneously given the proper conditions, such as in an elastic collision. In 1687, Isaac Newton published his Principia, which set out his laws of motion. It was organized around the concept of force and momentum. However, the researchers were quick to recognize that the principles set out in the book, while fine for point masses, were not sufficient to tackle the motions of rigid and fluid bodies. Some other principles were also required. By the 1690s, Leibniz was arguing that conservation of vis viva and conservation of momentum undermined the then-popular philosophical doctrine of interactionist dualism. (During the 19th century, when conservation of energy was better understood, Leibniz's basic argument would gain widespread acceptance. Some modern scholars continue to champion specifically conservation-based attacks on dualism, while others subsume the argument into a more general argument about causal closure.)
== Career == Middleton's cake-making business, now defunct, was inspired by reading that a mother's baking is a highly evocative childhood memory. He supplied baking kits so home bakers would be able to get all the ingredients in one place for adventurous creations such as "football cakes". He started baking in the family kitchen and expanded into a freight container and converted barns. Themed birthday cake baking kits were distributed by his parents' company, Party Pieces. Themed cakes were later provided for companies such as Jigsaw, 3 and Ralph Lauren. Middleton caused "shudders" at Buckingham Palace after taking part in a Hello magazine photoshoot for which he was commissioned to bake 21 cakes commemorating its 21st birthday, each iced with one of the magazine's front covers – amongst them, several members of the royal family, including Diana, Princess of Wales. The business won Smarta 100 and Haines Watts Young Entrepreneur awards. In April 2011, he registered three businesses: Nice Cakes, Nice Wine, and Nice Group London and planned to expand the Cake Kit Company. The Cake Kit Company was dissolved in 2015. In May 2020, Middleton launched Ella & Co, a mail order dog food company that offers freeze-dried, raw, organic dog food.
=== Cardiac === Chronic hyperglycemia (high blood sugar) injures the heart, even in patients without a history of heart disease or diabetes and is strongly associated with heart attacks and death in subjects with no coronary heart disease or history of heart failure.
Sources: en.wikipedia.org
=== 2000–2002: The beginning of the rivalry === 50 Cent's single "How to Rob" quickly became an underground hit throughout New York and 50 Cent soon began work on his major label debut Power of the Dollar, set for release in 2000. Despite 50 Cent's local success with "How To Rob", his local success paled in comparison to Ja Rule's following the release of Rule 3:36 later that same year. Tensions began to form beyond conflicts between the two crews and record labels. In February 2000, both 50 Cent and Ja Rule were scheduled to perform at the same Atlanta nightclub. Prior to the performances, music executive Chaz “Slim” Williams who was managing 50 Cent at the time, arranged a meeting between 50 Cent and Ja Rule to discuss ending their dispute. According to multiple accounts, the meeting escalated into a physical altercation after Ja Rule, who was holding a baseball bat, allegedly made threatening gestures toward 50 Cent. In response, 50 Cent reportedly attempted to strike Ja Rule, prompting a scuffle between the two. Accounts of the incident differ regarding what occurred next. 50 Cent has claimed to have punched Ja Rule, knocked him unconscious and took his chain while Ja Rule has maintained that he struck 50 Cent with the baseball bat before the two engaged in a physical struggle. Black Child, an associate of Ja Rule, later alleged that members of Ja Rule’s entourage chased 50 Cent through a nearby hotel following the incident.
=== Negative effects === As of 2017, the American Academy of Pediatrics says that fruit juice should not be given to children under the age of one due to its lack of nutritional benefit. For children ages one to six, intake of fruit juice should be limited to less than 4–6 oz (110–170 g) per day (about a half to three-quarters of a cup) due to its high sugar and low fiber content compared to fruit. Overconsumption of fruit juices may reduce nutrient intake compared to eating whole fruits and may produce diarrhea, gas, abdominal pain, bloating, or tooth decay. Overconsumption of fruits and fruit juice may contribute to dental decay and cavities via the effect of fruit acids on tooth enamel. Longitudinal prospective cohort studies showed a significantly increased risk of type 2 diabetes when juices with added sugars were consumed compared to eating whole fruits. A 2014 review found that a higher intake of sugar-sweetened fruit juice was significantly associated with a higher risk of type 2 diabetes. Overconsumption of fruit juice with added sugars has also been linked to childhood obesity. The American Journal of Public Health proposed that the Healthy Hunger-Free Kids Act of 2010 in the United States eliminate 100% fruit juices and substitute them instead with whole fruits.
Counter-Strike is a team-based multiplayer first-person shooter video game in which players play as Terrorists (T) or Counter-Terrorists (CT). Each game begins with both teams spawning simultaneously as one of eight possible default character models (four each for Counter-Terrorist and Terrorist). Each player begins with $800, two magazines of ammo, a knife, and a handgun: a Heckler & Koch USP for the Counter-Terrorists or a Glock 18c for the Terrorists. Players are usually allowed a few seconds before the round starts to purchase equipment but not move. They may purchase equipment whenever they are in a buy zone for their team. When players are killed, they become spectators for the rest of the round. They may typically watch the rest of the round from a variety of chosen observer modes. At the end of each round, players receive money for the next round: $3,500 for winning a round, $1,500 for losing one, and $300 for killing an enemy, up to a maximum total of $16,000. Players can be fined, or lose money, by killing a teammate or a hostage. Depending on the map, there are 3 possible objectives to win (in addition to eliminating all enemy team members):
Sources: en.wikipedia.org
== Services == The Instituto Universitario de Restauración del Patrimonio is divided into two areas: the area of intervention in the Pictorial and Sculptural Heritage and the area of intervention in the Architectural Heritage, and a Training and Dissemination area. The area of intervention in the pictorial and sculptural heritage operates in both basic research and applied research in seeking to acquire new knowledge to develop new products, techniques, processes, methods and systems that improve existing ones. The area of intervention in the Pictorial and Sculptural Heritage consist in restoration workshops:
It is also used in the preparation of sour pickles, cabbage, and other dishes. In Romania, dill (mărar) is widely used as an ingredient for soups such as 'borş' (pronounced "borsh"), pickles, and other dishes, especially those based on peas, beans, and cabbage. It is popular for dishes based on potatoes and mushrooms and may be found in many summer salads (especially cucumber salad, cabbage salad and lettuce salad). During springtime, it is used in omelets with spring onions. It often complements sauces based on sour cream or yogurt and is mixed with salted cheese and used as a filling. Another popular dish with dill as a main ingredient is dill sauce, which is served with eggs and fried sausages. In Hungary, dill is very widely used. It is popular as a sauce or filling, and mixed with a type of cottage cheese. Dill is also used for pickling and in salads. The Hungarian name for dill is 'kapor'. In Serbia, dill is known as 'mirodjija' and is used as an addition to soups, potato and cucumber salads, and French fries. It features in the Serbian proverb, "бити мирођија у свакој чорби" /biti mirodjija u svakoj čorbi/ (to be a dill in every soup), which corresponds to the English proverb "to have a finger in every pie". In Greece, dill is known as άνηθος (anithos). In antiquity it was used as an ingredient in wines that were called "anithites oinos" (wine with anithos-dill). In modern days, dill is used in salads, soups, sauces, and fish and vegetable dishes.
=== Biological === A kombucha culture is a symbiotic culture of bacteria and yeast (SCOBY), similar to mother of vinegar, containing one or more species each of bacteria and yeasts, which form a zoogleal mat known as a "mother". There is a broad spectrum of yeast species spanning several genera reported to be present in kombucha cultures, including species of Zygosaccharomyces, Candida, Kloeckera/Hanseniaspora, Torulaspora, Pichia, Brettanomyces/Dekkera, Saccharomyces, Lachancea, Saccharomycoides, Schizosaccharomyces, Kluyveromyces, Starmera, Eremothecium, Merimbla, Sugiyamaella. The bacterial component of kombucha comprises several species, almost always including the acetic acid bacteria Komagataeibacter xylinus (formerly Gluconacetobacter xylinus), which ferments alcohols produced by the yeasts into acetic and other acids, increasing the acidity and limiting ethanol content. The population of bacteria and yeasts found to produce acetic acid has been reported to increase for the first 4 days of fermentation, decreasing thereafter. K. xylinus produces bacterial cellulose, and is reportedly responsible for most or all of the physical structure of the "mother", which may have been selectively encouraged over time for firmer (denser) and more robust cultures by brewers. The highest diversity of kombucha bacteria was found to be on the 7th day of fermentation with the diversity being less in the SCOBY. Acetobacteraceae dominate 88 percent of the bacterial community of the SCOBY.
In 2014, Galloway opposed Western military action against Islamic State, which he called a "death cult", and instead advocated military action from the regional powers. In 2016, he supported Russian military action against Islamic State, saying: "I support the decision of the Russian government to come to the aid of the government in Syria because whatever faults it [the Syrian government] may have, whatever crimes it has committed, they are considerably fewer than the crimes committed by IS or would be committed by IS were they to come to power".
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.